

Cong Xue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8884640/publications.pdf>

Version: 2024-02-01

40
papers

1,434
citations

567281

15
h-index

330143

37
g-index

40
all docs

40
docs citations

40
times ranked

2926
citing authors

#	ARTICLE	IF	CITATIONS
1	EBV-driven LMP1 and IFN- γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. <i>Oncotarget</i> , 2014, 5, 12189-12202.	1.8	324
2	High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. <i>Oncotarget</i> , 2015, 6, 33972-33981.	1.8	159
3	High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. <i>OncoTargets and Therapy</i> , 2014, 7, 1475.	2.0	149
4	Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations. <i>PLoS ONE</i> , 2014, 9, e85245.	2.5	125
5	Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 50.	7.4	113
6	National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. <i>Lung Cancer</i> , 2012, 77, 371-375.	2.0	112
7	PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival. <i>Oncotarget</i> , 2015, 6, 33019-33032.	1.8	69
8	Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1827.	4.3	40
9	Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysis. <i>Oncotarget</i> , 2016, 7, 20093-20108.	1.8	31
10	A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population. <i>Scientific Reports</i> , 2014, 4, 7268.	3.3	28
11	Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). <i>Clinical Cancer Research</i> , 2022, 28, 637-645.	7.0	27
12	Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo. <i>Cancer Communications</i> , 2018, 38, 1-9.	9.2	23
13	Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature. <i>Cancer</i> , 2020, 126, 3837-3846.	4.1	20
14	The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 55-62.	6.3	19
15	A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China. <i>Chinese Journal of Cancer</i> , 2016, 35, 40.	4.9	18
16	Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. <i>Oncologist</i> , 2018, 23, 603-616.	3.7	17
17	A Novel Ferroptosis-Related Gene Signature Predicts Overall Survival of Breast Cancer Patients. <i>Biology</i> , 2021, 10, 151.	2.8	17
18	Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials. <i>OncoTargets and Therapy</i> , 2014, 7, 1851.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. <i>Cancer Communications</i> , 2021, 41, 171-182.	9.2	15
20	Tumor-infiltrating lymphocytes predict prognosis of breast cancer patients treated with anti-Her-2 therapy. <i>Oncotarget</i> , 2017, 8, 5219-5232.	1.8	15
21	In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1299.	4.3	13
22	An investigation of symptom burden and quality of life in Chinese chemo-naïve advanced lung cancer patients by using the Instrument-Cloud QOL System. <i>Lung Cancer</i> , 2014, 84, 301-306.	2.0	12
23	Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , 2015, 34, 177-83.	4.9	10
24	Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 1003-1003.	1.6	10
25	QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. <i>Scientific Reports</i> , 2015, 5, 11934.	3.3	9
26	Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 619-628.	2.5	9
27	Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment. <i>Scientific Reports</i> , 2015, 5, 10648.	3.3	7
28	Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 739134.	2.8	5
29	Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 1219.	2.0	4
30	Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4897.	4.3	4
31	Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy—A systematic review and meta-analysis. <i>Clinical Immunology</i> , 2022, 236, 108927.	3.2	4
32	Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience. <i>Oncotarget</i> , 2016, 7, 63722-63729.	1.8	2
33	Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0148849.	2.5	2
34	Immune checkpoint inhibitor plus anti-EGFR target therapy plus chemotherapy in patients with locally advanced penile squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, e17016-e17016.	1.6	2
35	Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti-PD-1/PD-L1-Based Therapy. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 621883.	3.5	2
36	Operable Breast Cancer of the Inner Hemisphere Is Associated with Poor Survival. <i>Journal of Breast Cancer</i> , 2015, 18, 36.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1173.	4.3	1
38	Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 521-521.	1.6	1
39	Endocrine treatment-related symptoms and outcomes in breast cancer: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, e12001-e12001.	1.6	0
40	Two-year follow-up of pretreatment anti-mullerian hormone (AMH) to predict for resumption of mense after chemotherapy in premenopausal hormone-receptor (HR+) positive early breast cancer (eBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e12511-e12511.	1.6	0